Lung cancer is a heterogeneous disease, and the availability of comprehensive genomic
profiling has allowed for the characterization of its molecular subtypes. This has increased …

Systemic therapy for non-small cell lung cancer (NSCLC) has undergone a dramatic
paradigm shift over the past decade. Advances in our understanding of the underlying …

The rapid expansion of novel technologies in cancer research over the past several years
has led to a dramatically improved understanding of the molecular biology of lung cancer …

The high morbidity and mortality of non-small cell lung cancer (NSCLC) have always been
major threats to people's health. With the identification of carcinogenic drivers in non-small …

The diagnostic testing, treatment and prognosis of non-small cell lung cancer (NSCLC) has
undergone a paradigm shift since the discovery of sensitizing mutations in the epidermal …

Abstract Purpose of Review Lung cancer remains the leading cause of cancer-related
mortality worldwide. Genetic and molecular profiling of non-small cell lung cancer (NSCLC) …

The last decade has witnessed the development of oncogene-directed targeted therapies
that have significantly changed the treatment of non-small-cell lung cancer (NSCLC). In this …

In this review, the authors aim to provide an overview of current molecular targeted therapies
for NSCLC, to propose an algorithm for clinical application of presently available treatment …

Lung cancer is a highly heterogeneous disease often driven by well-characterized driver
mutations. Although the best studied are common alterations in the epidermal growth factor …

Lung cancer has traditionally been classified by histology. However, a greater
understanding of disease biology and the identification of oncogenic driver alterations has …